<DOC>
	<DOCNO>NCT02300103</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability treatment sofosbuvir ( SOF ) /velpatasvir ( VEL ; GS-5816 ) ribavirin ( RBV ) 24 week adults chronic hepatitis C virus ( HCV ) infection participate prior Gilead sponsor study achieve sustain virologic response ( SVR ) .</brief_summary>
	<brief_title>Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin Chronic HCV Infected Adults Who Participated Prior Gilead Sponsored HCV Treatment Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing able provide write informed consent HCV genotype determine Central Laboratory HCV RNA &gt; LLOQ screening Participated complete Gilead sponsor HCV treatment study direct act antiviral ( DAA ) contain regimen . Male female childbearing potential must agree use protocol specify method ( ) contraception Current prior history : Clinicallysignificant illness ( HCV ) major medical disorder may interfere treatment , assessment compliance protocol ; individual currently evaluation potentially clinicallysignificant illness ( HCV ) also exclude . Screening ECG clinically significant abnormality Laboratory result outside acceptable range screen Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>